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A B S T R A C T
Purpose: Seizures are the most common initial symptom in patients with low-grade gliomas, and
approximately 30% of these patients still suffer from epilepsy after gross-total resection of the tumour.
We examined the relationship between the overexpression of ki-67 in WHO grade II gliomas and seizure
control.
Methods: A series of 93 histologically conﬁrmed WHO grade II glioma tissues were analysed through
immunohistochemical staining for ki-67 expression. Follow-up visits regarding seizure control were
scheduled at 12 months. The Engel classiﬁcation was used to categorise patients’ seizure status.
Results: Of the 93 patients analysed, 65 (66.3%) patients initially presented with seizures. A total of 36
patients were diagnosed with WHO grade II oligodendrogliomas, 29 patients had oligoastrocytomas and
28 patients had astrocytomas. Ki-67 was over-expressed in 15 patients. One year after surgery poor
seizure control was observed in 11 of these patients. In contrast, low ki-67 expression (<10%) was found
in 78 patients. Poor seizure control was observed in 36 patients (difference between ki-67 over- and low
expression groups P = 0.002). Logistic regression analysis revealed that patients with gross-total
resection achieved better seizure control while ki-67 overexpression and age below 38 years were poor
seizure control factors explained of the variance of seizure outcome (OR: 0.382, 4.354 and 1.822,
respectively).
Conclusions: In WHO grade II gliomas, Ki-67 is a molecular marker which predicts poor seizure control of
glioma patients after the resection of the tumour. Gross-total resection, ki-67 overexpression and age
below 38 years signiﬁcantly affect seizure prognosis.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epileptic seizures are one of the most frequent presenting
symptoms of gliomas, particularly in low-grade gliomas. Approxi-
mately 80%1 of glioma patients will experience at least one seizure
during the course of the disease, and the aetiology of glioma-
related seizure is most likely multifactorial and complex, thereby
remaining poorly understood. The risk of seizure development is
strongly associated with the histological types and WHO scales of
gliomas.2 Many studies have indicated that low-grade gliomas,
which grow slowly and invade normal surrounding brain tissue,
are most likely to cause epilepsy.2–4 The mechanisms by which
high-grade gliomas may cause epilepsy are probably different,
involving more signiﬁcant tissue damage, such as necrosis or
hemosiderin deposition.2 Tumour localisation3 is another factor* Corresponding author. Tel.: +86 18980601506.
E-mail address: qingmao2000@163.com (M. Qing).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.08.004strongly affecting seizure risk. Patients with glioma in the
temporal, insular or frontal lobes have a higher risk of developing
epileptic seizures preoperatively than patients with occipital and
deep-seated lesions. Interestingly, based on a study of 332 low-
grade glioma patients, Chang et al.4 observed that seizure
recurrence was associated with tumour progression and that the
over-expression of certain biomarkers (P53, Ki-67, MMP-9 and
MGMT) might be correlated with poor survival in patients with
gliomas. Therefore, it is possible that there might be a relationship
between these different genetic factors and postoperative seizure
outcomes.5 However, to date, biomarkers that predict pre- or
postoperative epileptic seizures have not been identiﬁed.
Ki-676 is an excellent marker to determine the growth fraction
of a given cell population, and the expression of ki-67 is a routine
test performed in many neurosurgery centres to predict the level of
malignancy of gliomas and the prognosis of patients. The aim of
this retrospective study was to investigate whether the over-
expression of ki-67 (10%) in diffusely inﬁltrating glioma is
associated with poor postoperative seizure control. We excludedvier Ltd. All rights reserved.
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Fig. 1. Procedure for the selection of glioma patients in this study.
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frequency of ki-67 overexpression and low frequency of epileptic
seizures. In addition, the treatment strategies for low- and high-
grade gliomas are different, which might contribute to differences
in the prognosis of the patients, including seizure outcomes. We
also excluded WHO grade I gliomas because the morbidity of these
tumours was much lower compared with other tumour types, and
many of the patients preferred non-operative treatments (Fig. 1).
2. Materials and methods
2.1. Patients
Patients at the Glioma Treatment Centre, West China Hospital,
Chengdu, China with newly diagnosed and histologically con-
ﬁrmed WHO grade II gliomas between January 2011 and January
2012 were included. The ethic committee of the hospital approved
the study, and informed consent was obtained from all patients.
Patients who met the following criteria were enrolled in this
research:
(1) 17 years of age or older,
(2) histopathologically conﬁrmed diagnosis of WHO grade II
glioma,
(3) available documentation of ﬁrst tumour symptoms,
(4) MRI conﬁrmation of invasion of cortex or subcortical white
matter and
(5) gliomas only in the occipital lobe
(6) availability of either fresh, frozen tumour or parafﬁn-embed-
ded tumour tissue. In total, 93 patients were included.
2.2. Clinical categorisation and follow-up
An independent neurologist (Liu Shuang), who was not
involved the treatment of the patients and blinded to the results
of ki-67 expression, identiﬁed patients’ initial symptoms. The
initial symptoms were categorised into generalised seizures,
partial seizures and non-seizure symptoms. Epilepsy subtypes
were classiﬁed according to the International League against
Epilepsy (ILAE 2001). The patients were followed up by telephone
or in the outpatient clinic at 12th months after the tumourresection, and the Engel classiﬁcation was used to categorise
seizure outcome after surgery. For the outcome analyses, Engel
classiﬁcation was dichotomised as class I (completely seizure free)
versus classes II–IV (not seizure free).
2.3. Histopathology and the expression of ki-67
At least two experienced neuropathologists re-deﬁned all of the
histological tissues according to the 2007 WHO classiﬁcation of
brain tumours. If the two neuropathologists did not agree on the
deﬁnition of the pathological type, a third neuropathologist re-
evaluated the tumour tissue and provided a deﬁnitive opinion.
Immunohistochemical staining for ki-67 was performed on
formalin-ﬁxed, parafﬁn-embedded tissue sections following the
manufacturer’s standard protocol (mouse monoclonal antibody-
MIB-1, Maxim, USA). Two independent observers individually
reviewed and scored each slide stained for Ki-67.
2.4. MRI characteristics
MRI scans were re-examined. Tumours were considered to be
inﬁltrating the frontal, parietal, temporal lobes and insula when
there was inﬁltration extending more than 1 cm into the cortex or
subcortical white matter on FLAIR or T2 images. If tumours affected
multiple lobes, inﬁltration of each lobe was counted (Fig. 2).
2.5. Statistical analysis
All statistical analyses were performed using SPSS version 17.0,
and for all analyses, a type I error of a = 5% was deﬁned. Univariate
analyses were performed using the chi-square test for dichoto-
mous variables and the Mann–Whitney U-test for continuous non-
parametric data.
3. Results
A total of 93 patients with newly diagnosed and histologically
conﬁrmed WHO grade II gliomas were included in the analysis. Of
these patients, 36 were diagnosed with WHO grade II oligoden-
drogliomas, 29 patients had oligoastrocytomas and 28 astrocyto-
mas. There were 53 (55.5%) males and 40 (45.5%) females; the
median age at initial resection of the glioma was 48.7 years.
Fig. 2. Preoperative and 3-month postoperative MRI scans in patients who underwent surgery for WHO grade II astrocytoma. (A and B) Tumour-inﬁltrated temporal lobe with
contrast enhancement and T2 signal abnormality. (C and D) Gross-total resection in T1 and T2 signals.
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41 cases, the parietal lobe in 14 cases and the insular lobe in 8
cases.
Patients with and without seizures as the initial symptom did
not differ in terms of median age at presentation (48.6 vs. 48.9
years, respectively; P = 0.8772, F test). The most common type of
preoperative seizure types were secondary generalised (41.5%)
followed by simple partial (30.7%), complex partial (23.8%) and a
combination of partial and generalised seizures (4%).
The majority of patients (69.8%) were completely seizure free
(Engel class I) at 12 months after glioma surgery, the remaining
patients were not seizure free (Engel classes II–IV). Without special
guidelines for postoperative prevention or the treatment ofTable 1
Primary symptoms of the 93 glioma grade II patients according to ki-67 expression
status.
Symptoms ki-67  10% ki-67 < 10
Generalised seizures 4 23
Simple partial seizures 2 18
Complex partial seizures 2 13
Combination of partial and generalised seizures 1 2
Headaches 5 13
Focal neurological deﬁcits 1 7
Incidental ﬁndings NA 2
Total number of seizuresa 9 56
Total number of patients 15 78
a The total number of patients with seizures.glioma-related epilepsy, antiepileptic drugs (AEDs) were used
according to the preference and experience of the doctors. The
most commonly used AED was valproic acid (>95%), followed by
levetiracetam and carbamazepine. Eleven patients were treated
with temozolomide according to the standard 5-day schedule
every 28 days (150 mg per square metre for the ﬁrst cycle, 200 mg
per square metre beginning with the second cycle) and 85 patients
received radiotherapy according to National Comprehensive
Cancer Network (NCCN) Guidelines for Central Nervous System
Cancers (Table 1).
Ki-67 was over-expressed in 15 glioma tissues, including 3
astrocytoma, 6 oligodendroglioma and 6 oligoastrocytoma sam-
ples. A total of 11 of these 15 patients experienced poor seizure
control at 12 months follow-up. Oligodendrogliomas and oligoas-
trocytomas showed ki-67 overexpression compared with astrocy-
tomas. Seizures more frequently occurred in tumours inﬁltrating
the temporal lobe (34/41, 82.9%), followed by the frontal lobe (33/
45, 75.0%), insula (5/8, 62.5%), and parietal lobe (8/14, 57.1%)
(Tables 2–4).
4. Discussion
Over 80% of glioma patients will experience at least one seizure
during the course of their disease, and approximately one-third of
these patients will develop seizures, which are refractory to
traditional anti-epileptic drugs, even after gross-total tumour
resection.7 Uncontrolled seizures have adverse effects on the
quality of life of glioma patients, particularly of those who have
Table 2
Clinical and demographic characteristics of 93 patients before surgerya
Parameter Total (%) Seizures (%) No seizures (%) P-value
Number of patients 93 65 (69.8) 28 (30.2)
MRI size, cm (range) 4.8(2.0–8.8) 4.9(2.5–8.8) 4.7(2.0–8.3) 0.973(U-text)
Tumour location
Left/right ratio 1.14 1.24 0.96 0.203
Frontal 45(45.9) 33(50.7) 18(64.2) 0.523
Temporal 41(41.8) 34(52.3) 17(60.7) 0.690
Parietal 14(14.2) 8(12.3) 6(21.4) 0.366
Insular 8(8.1) 5(7.6) 3(10.7) 0.698
Tumour pathology
Astrocytoma 28(30.1) 21(32.3) 7(25.0) 0.601
Oligoastrocytoma 29(29.5) 23(35.3) 6(21.4) 0.323
Oligodendroglioma 36(38.7) 21(32.3) 15(53.5) 0.212
a Unless otherwise indicated, the values represent the number of patients, and the percentages are shown in parentheses.
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for glioma-related seizures have not previously been identiﬁed. In
the present study, we retrospectively analysed a series of 93
histologically conﬁrmed WHO grade II glioma patients, who
underwent their ﬁrst tumour resection. We demonstrated an
association of high ki-67 expression and poor postoperative
seizure outcome. Ki-67 expression was assessed by immunohisto-
chemical staining.
Thirty-six patients (38.7%) of our series were found to have
oligodendrogliomas, a slightly higher proportion than in the study
by You et al.1 and van Breemen et al.9 Given that oligoden-
drogliomas and oligoastrocytomas are more likely to exhibit Ki-67
over-expression than astrocytomas, this could explain our ﬁndings
and histological subgroup analyses should be performed in future
studies.
Many studies8,10–12 have demonstrated that the tumour
localisation inﬂuences the likelihood of epileptic activity. Occipital
lobe neoplasms are least likely to cause tumour-related epilepsy;
thus, we excluded occipital gliomas from the present study. Liigant
and coworkers13 showed that the seizure activity is rarely
observed in infratentorial and sellar tumours, unless these lesions
inﬁltrate the cerebral cortex, so these tumours were also excluded
from our series. In the present study, we observed that seizures
primarily occurred in glioma-inﬁltrated temporal lobe, consistent
with the results of previous studies.11,12 Interestingly, no insular
gliomas, showing ki-67 overexpression were observed, potentially
reﬂecting the sample small size. Moreover, insular glioma-relatedTable 3
Seizure prognosis at 12 months after tumour resection.
12 month follow-up
Variable Total Seizure
free (%)
Seizure
uncontrolled (%)
P value
No. Patients 93 57(61.2) 36(39.7)
Ki-67 status 0.002
Ki-67  10% 15(16.1) 3(5.2) 12(33.3)
Ki-67 < 10% 78(83.9) 54(94.8) 24(66.7)
WHO grade II
Astrocytoma 28(30.1) 18(31.5) 10(27.8) 0.775
Oligoastrocytoma 29(29.5) 16(28.0) 13(36.1) 0.557
Oligodendroglioma 36(38.7) 23(40.3) 13(36.1) 0.785
Extent of reception 0.001
Gross total 36(34.4) 29(50.8) 7(19.4)
Subtotal 57(65.6) 28(49.1) 29(80.6)
AED treatment 65(69.8) 37(64.9) 28(77.7) 0.582
KPS score 80 81(87.0) 54(94.8) 27(75.0) 0.462
Tumour status
Progression free 85(91.3) 55(96.4) 30(83.3)
Progression 8(8.7) 2(3.5) 6(16.7)
Adjuvant therapy
Radiotherapy 85(92.4) 52(91.2) 33(91.6) 0.988
Chemotherapy 11(11.9) 6(10.5) 5(13.8) 0.665seizures could represent a unique seizure subtype with its own
pathogenesis and genetic characteristics.8
The level of expression of ki-67 was not related to the
preoperative seizure occurrence risk. However, we observed that
gross-total resection, ki-67 overexpression and age below 38 years
signiﬁcantly impacted the seizure prognosis. At follow up 12
months after resection approximately 91.3% of the 93 glioma
patients showed no tumour progression, 8 patients had tumour
progression and 1 patient had died. We also observed that tumour
progression was typically accompanied by seizure recurrence,
consistent with the results of Chang EF4, who performed a follow
up study of 332 low-grade glioma patients. Interestingly, in that
study young age was associated with relatively poor seizure
control, suggesting that elderly patients are more likely to present
with high-grade gliomas associated with a lower risk of inducing
seizures.
The role of ki-67 in glioma-related epilepsy remains unknown,
whereas the development of epilepsy through tumoural or
peritumoural changes in glioma patients has been demonstrated
in many previous studies.14,15 Peritumoural amino acid16 and
receptor changes17 have been observed in rat epilepsy models rats
or the brain tissues from glioma patients, and many studies have
suggested that this protein could be a target for the treatment of
glioma-related epilepsy. Buckingham et al.18 showed that gluta-
mate release from primary brain tumours induces epileptic
activity, and the inhibition of the Xc system through sulphasa-
lazine eliminates epileptiform activity. Sontheimer19 proposed
that the invasion of gliomas into the peritumoural zone is partially
mediated through chloride (Cl) channels that facilitate rapid cell
deformation to traverse the conﬁned extracellular space, suggest-
ing that glioma cells induce excitotoxic neuronal cell death
through the release of high levels of glutamate, thereby facilitating
invasion. Tumoural or peritumoural changes play important roles
in the induction of epileptiform activity,20 and Ki-67 is most likely
a cellular marker for proliferation, strictly associated with cell
proliferation in human cells. Thus, we propose that the prolifera-
tion of the tumour cells plays a vital role in seizure control. When
high levels of ki-67 expression are observed in tumour tissue,
residual tumour tissue may inﬂuence the peritumoural microen-
vironment even after gross-total resection, explaining why glioma
patients with strong ki-67 expression have a poor seizure
prognosis.Table 4
Predictors of postoperative seizure controla
Variable OR 95% CI P value
Gross-total resection 0.382 0.125–0.964 0.037
Ki67" 4.354 1.288–14.720 0.012
Age <38 years 1.822 1.326–3.350 0.003
a Results of logistic regression analysis.
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related epilepsy, although the unique pathogenesis of this
condition is different from any other type of epilepsy. In this
study, AEDs were used according to the custom of the hospital or
the preference of the doctor. However, the use of ADEs in patients
without a history of epilepsy before surgery to prevent epileptic
activity remains under debate. Meta-analysis21 shows that for
patients who do not present with seizures preoperatively, AEDs
have no signiﬁcant preventative effect postoperatively. In the
present study, ADEs were stopped within two weeks after surgery
in the patients without seizures as the initial symptom; however,
this subgroup was classiﬁed according to ki-67 status rather than
seizure history before surgery, and no signiﬁcant differences were
observed in our analysis. Because of the limited sample size, we
could not perform additional analyses taking account of AED use.
Based on the ﬁndings of our study the use of AEDs as preventative
postoperative treatment for glioma-associated seizures could be
tested in a prospective randomised controlled trial in patients with
ki-67 expression >10%.
In the present study, we observed a correlation between ki-
67 expression and clinical symptoms. However, this study has
some limitations. A 12-month follow-up period is relatively
short for patients with WHO grade II gliomas, and our ﬁndings
should be conﬁrmed with a longer follow-up period. Further-
more, because of the limited budget, our patient cohort was too
small for further subgroup analysis; thus, more patients should
be included in future studies. The most commonly used AED at
our centre is Valproic acid, an old generation ADE, thus the new
AED, levetiracetam, should be used upon patient request or
when the seizures are uncontrolled through treatment with only
Valproic acid. Finally, the association we have found does
not tell us anything about causality. Future experimental
studies looking at the relationship of ki-67 expression and
seizures will be needed to explore whether there is a direct
causal link.
5. Conclusions
The results of the present study suggest a new role for ki-67 in
WHO grade II gliomas. These data suggest that ki-67 over-
expression is a predictor or poor postoperative seizure control in
patients with WHO grade II gliomas. Gross-total resection, ki-67
overexpression and age below 38 years signiﬁcantly impacted
seizure prognosis in this study. The postoperative use of
preventative AEDs may be considered in glioma patients
exhibiting ki-67 overexpression, even without a history of
epilepsy.Conﬂict of interest statement
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